BF-B vs JBS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard shows a Piotroski F-Score of 6/9, indicating stable financial health, but the absence of an Altman Z-Score limits distress risk assessment. Despite solid profitability metrics like a 29.44% operating margin and 20.67% ROE, the company faces declining revenue and earnings, with YoY revenue down 5.40% and earnings down 13.90%. The stock trades above the Graham Number of $18.30 at $27.57, supported by a 3.26% dividend yield and analyst target of $30.26, but weak recent earnings surprises and insider selling temper optimism.
JBS presents as a classic value play with a Piotroski F-Score of 4/9, indicating stable but not robust financial health. The stock currently trades at a discount to its Graham Number ($18.61) and offers a highly attractive 8.31% dividend yield supported by a very low payout ratio. While revenue growth remains strong at 15.5%, the decline in earnings growth and a high debt-to-equity ratio (2.52) are the primary headwinds. The strong ROE of 25.26% and a 'strong_buy' analyst consensus suggest significant upside potential despite current bearish technical trends.
Compare Another Pair
Related Comparisons
BF-B vs JBS: Head-to-Head Comparison
This page compares Brown-Forman Corporation (BF-B) and JBS N.V. (JBS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.